Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417005 | 0.76 | SMN1; SMN2 (0.60) | OR51E2SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL8416906 | 0.76 | SMN1; SMN2 (0.60) | OR51E2SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL125700 | 0.76 | SMN1; SMN2 (0.60) | OR51E2SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL28231517 | 0.74 | CYP2C9 (0.37) | OR51E2SMN1; SMN2CYP2C9TSHR | |
| SCHEMBL7063820 | 0.73 | — | — | |
| SCHEMBL1011058 | 0.72 | ALDH1A1 (0.32) | OR51E2SMN1; SMN2 | |
| SCHEMBL17933644 | 0.72 | ALDH1A1 (0.32) | OR51E2SMN1; SMN2 | |
| SCHEMBL19912992 | 0.68 | TET2 (0.33) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| SCHEMBL19912986 | 0.68 | — | — | |
| SCHEMBL23117702 | 0.67 | ENPEP (0.40) | OR51E2SMN1; SMN2GABRR1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057897-A1 | Synthesis of Furans from Sugars Via Keto Intermediates | BP CORPORATION NORTH AMERICA INC. (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057897-A1 | Synthesis of Furans from Sugars Via Keto Intermediates | KHK, HPD, ALDOA | OR51E2 3528/4885SMN1; SMN2 4421/4885TET2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.